I am an assistant professor of molecular and gynecologic surgical pathology at MD Anderson Cancer Center and have extensive training regarding the techniques employed within the CLIA certified Molecular Diagnostics Laboratory here at MD Anderson. This includes data analysis of next generation sequencing panels for tumor somatic mutation testing, methylation and copy number variant arrays. Along with many others, my primary interest is in cancer immunotherapy, which I believe is the most promising field of cancer therapy with a unique potential for long-term recurrence free survivals. Recent FDA approval of several immune checkpoint inhibitors for myriad indications including increased tumor mutational burden has convinced me that cancer immunotherapies will contribute to an increasing proportion of cancer therapy regimens going forward. It seems inevitable that there will be increasing demand for in-house testing of biomarkers for immunotherapy, including methylation and copy number variant assays, with increasing utilization by oncologists. I plan to be a part of this expansion into immune therapy testing in the future.